RBC Capital analyst Kennen MacKay initiated coverage of Clovis with an Outperform rating and $17 price target. The analyst notes that the company's reported Rubraca sales in Q4 were in line with its pre-reporting guidance, as the program generated slight growth globally. MacKay notes however that the management has maintained its view about the potential for stepped up increases in Rubraca growth in 2020, as he continues to see the drug's approval and launch in prostate cancer as critical to its longer-term commercial prospects and his bullish thesis.